Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

NCT04091750 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Cabozantinib

Sponsor

Georgetown University

Collaborators

[object Object]
[object Object]
[object Object]